ReAlta Life Sciences News and Activities

Acquisition, funding and merger involving ReAlta Life Sciences.

• ReAlta Life Sciences has just announced a $40 Million fundraising (posted on April 16 2026).

View the org chart displaying its 12 main executives

Most searched biographies at ReAlta Life Sciences

• Howard Berman, Chairman of the Board and Chief Executive Officer
• Buzz Heidt, Director
• Buddy Gadams, Director

Popular executive movements at ReAlta Life Sciences

• Ellen Lubman, Chief Business Officer, has left the company  (posted on March 24 2026).
• Kia Motesharei, who was Director, is promoted to President and Chief Operating Officer  (posted on March 24 2026).
• Dawn Buchanan, Vice President, Head of Clinical Operations, has left the company  (posted on March 24 2026).

Click here to view some more movements at ReAlta Life Sciences

Create your alert
to follow the executive moves at ReAlta Life Sciences.

ReAlta Life Sciences has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by ReAlta Life Sciences

• ReAlta Raises $40M to Advance HIE Phase 2 Drug Program
• ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO - ReAlta Life Sciences
• ReAlta Life Sciences Announces Appointment of Kia Motesharei, Ph.D. to Board of Directors - Realta Life Sciences
• News about ReAlta Life Sciences
• ReAlta Life Sciences Announces Appointment of Jonathan Rigby to Board of Directors - Realta Life Sciences
• News about ReAlta Life Sciences
• ReAlta Announces Promising Phase 2 Data Demonstrating Rapid Clinical Responses and Target Engagement in Steroid-Refractory Acute GvHD at the ASH 2025 Annual Meeting - Realta Life Sciences
• ReAlta Life Sciences to Present RLS-0071 (pegtarazimod) Clinical Data at 2025 American Society of Hematology Annual Meeting - Realta Life Sciences
• ReAlta Life Sciences Receives EMA Orphan Drug Designation for RLS-0071 (pegtarazimod) for the Treatment of Graft-Versus-Host Disease - Realta Life Sciences
• ReAlta Life Sciences Strengthens Management Team with the Appointment of Biotechnology Business Leader Ellen Lubman, MBA as Chief Business Officer - Realta Life Sciences
• View more press releases Close

Social media about ReAlta Life Sciences

• ReAlta Life Sciences on Wikipedia, Google News & Yahoo Finance
• ReAlta Life Sciences on LinkedIn, X (Twitter) & YouTube